Atara Biotherapeutics (ATRA) Competitors

$9.53 +0.09 (+0.95%)

As of 04:00 PM Eastern

ATRA vs. ORIC, RCKT, ARCT, UPB, and LYEL

Should you buy Atara Biotherapeutics stock or one of its competitors? Atara Biotherapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Rocket Pharmaceuticals (RCKT), Arcturus Therapeutics (ARCT), Upstream Bio (UPB), and Lyell Immunopharma (LYEL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Oric Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Atara Biotherapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A

Oric Pharmaceuticals currently has a consensus price target of $19.45, suggesting a potential upside of 52.70%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential downside of 0.31%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Oric Pharmaceuticals had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 0 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.95 beat Atara Biotherapeutics' score of 0.95 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oric Pharmaceuticals	Positive
Atara Biotherapeutics	Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Oric Pharmaceuticals' return on equity of -35.35% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Rocket Pharmaceuticals' return on equity of -52.77% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Atara Biotherapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential downside of 0.31%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 126.16%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Atara Biotherapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 0 mentions for Atara Biotherapeutics. Rocket Pharmaceuticals' average media sentiment score of 1.00 beat Atara Biotherapeutics' score of 0.95 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Rocket Pharmaceuticals	Positive

Summary

Rocket Pharmaceuticals beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Atara Biotherapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

Atara Biotherapeutics has a net margin of -269.42% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Arcturus Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A
Arcturus Therapeutics	$82.03M	5.39	-$65.78M	-$3.31	N/A

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 1 mentions for Arcturus Therapeutics and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Arcturus Therapeutics' score of -0.11 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Arcturus Therapeutics	Neutral

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential downside of 0.31%. Arcturus Therapeutics has a consensus price target of $23.00, suggesting a potential upside of 47.81%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Arcturus Therapeutics beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Upstream Bio?

Atara Biotherapeutics (NASDAQ:ATRA) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Atara Biotherapeutics has higher revenue and earnings than Upstream Bio. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A
Upstream Bio	$2.85M	116.84	-$143.44M	-$2.90	N/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Atara Biotherapeutics has a net margin of -269.42% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 0.31%. Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 387.94%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

In the previous week, Upstream Bio had 9 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 9 mentions for Upstream Bio and 0 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.95 beat Upstream Bio's score of 0.51 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Upstream Bio	Positive

Summary

Atara Biotherapeutics beats Upstream Bio on 9 of the 17 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Atara Biotherapeutics (NASDAQ:ATRA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Atara Biotherapeutics has higher revenue and earnings than Lyell Immunopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.79	$32.69M	-$1.18	N/A
Lyell Immunopharma	$40K	8,771.00	-$274.45M	-$12.83	N/A

Atara Biotherapeutics presently has a consensus target price of $9.50, suggesting a potential downside of 0.31%. Lyell Immunopharma has a consensus target price of $40.86, suggesting a potential upside of 185.32%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Lyell Immunopharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Atara Biotherapeutics has a net margin of -269.42% compared to Lyell Immunopharma's net margin of -920,285.25%. Atara Biotherapeutics' return on equity of -79.12% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Atara Biotherapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lyell Immunopharma had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 1 mentions for Lyell Immunopharma and 0 mentions for Atara Biotherapeutics. Lyell Immunopharma's average media sentiment score of 1.67 beat Atara Biotherapeutics' score of 0.95 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Positive
Lyell Immunopharma	Very Positive

Summary

Atara Biotherapeutics and Lyell Immunopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.76M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-8.08	12.66	273.28	25.38
Price / Sales	0.79	1,309.16	613.48	92.60
Price / Cash	1.94	106.87	77.82	52.26
Price / Book	-2.58	16.29	12.89	6.14
Net Income	$32.69M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.03%	-1.37%	-0.33%	-1.47%
1 Month Performance	11.46%	11.07%	6.51%	2.47%
1 Year Performance	-24.54%	53.71%	25.19%	15.84%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	1.5006 of 5 stars	$9.53 +1.0%	$9.50 -0.3%	-23.5%	$94.76M	$120.77M	N/A	330	Positive News
ORIC Oric Pharmaceuticals	3.0644 of 5 stars	$13.46 -5.2%	$19.45 +44.5%	+26.5%	$1.47B	N/A	N/A	80	Positive News
RCKT Rocket Pharmaceuticals	3.2819 of 5 stars	$3.53 +0.6%	$8.57 +142.8%	+19.1%	$385.31M	N/A	N/A	240	Analyst Forecast
ARCT Arcturus Therapeutics	2.2854 of 5 stars	$14.34 +6.6%	$20.00 +39.5%	+0.2%	$382.29M	$18.72M	N/A	180	Analyst Forecast High Trading Volume
UPB Upstream Bio	2.053 of 5 stars	$6.61 -5.2%	$29.67 +348.8%	-68.0%	$381.75M	$3.16M	N/A	38	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, RCKT, ARCT, UPB, and LYEL

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Summary

How does Atara Biotherapeutics compare to Upstream Bio?

Summary

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, RCKT, ARCT, UPB, and LYEL

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Which has more risk & volatility, ORIC or ATRA?

Which has preferable valuation and earnings, ORIC or ATRA?

Do analysts rate ORIC or ATRA?

Does the media prefer ORIC or ATRA?

Do insiders and institutionals hold more shares of ORIC or ATRA?

Is ORIC or ATRA more profitable?

Summary

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Is ATRA or RCKT more profitable?

Which has more volatility and risk, ATRA or RCKT?

Do insiders & institutionals hold more shares of ATRA or RCKT?

Do analysts prefer ATRA or RCKT?

Which has better earnings and valuation, ATRA or RCKT?

Does the media favor ATRA or RCKT?

Summary

How does Atara Biotherapeutics compare to Arcturus Therapeutics?

Which has more volatility and risk, ATRA or ARCT?

Is ATRA or ARCT more profitable?

Do insiders and institutionals have more ownership in ATRA or ARCT?

Which has stronger earnings & valuation, ATRA or ARCT?

Does the media refer more to ATRA or ARCT?

Do analysts rate ATRA or ARCT?

Summary

How does Atara Biotherapeutics compare to Upstream Bio?

Which has preferable earnings and valuation, ATRA or UPB?

Do institutionals & insiders hold more shares of ATRA or UPB?

Is ATRA or UPB more profitable?

Do analysts recommend ATRA or UPB?

Which has more risk & volatility, ATRA or UPB?

Does the media favor ATRA or UPB?

Summary

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Which has better earnings & valuation, ATRA or LYEL?

Do analysts prefer ATRA or LYEL?

Is ATRA or LYEL more profitable?

Which has more risk & volatility, ATRA or LYEL?

Do institutionals and insiders have more ownership in ATRA or LYEL?

Does the media refer more to ATRA or LYEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools